Market Research Report: Cytiva
Company Overview
Name: Cytiva
Mission of the Company: _"At Cytiva, we envision a world in which access to life-changing therapies transforms human health. Our wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery."_
Founding and Founders: No information is available
Key People: Pierre-Alain Ruffieux, Chief Operating Officer
Headquarters: No information is available
Number of Employees: 15,000 associates
Revenue of the Company: No information is available
Primary Recognition:
- Part of Danaher, a global science and technology leader.
- Recognized for antibody purification.
Products
1. Bioprocessing Solutions
- Description: End-to-end solutions supporting the journey from discovery to delivery.
- Key Features:
- Support for process development, intensification, and scaling.
- Suitable for monoclonal antibodies, antibody variants, viral vectors, vaccines, recombinant proteins, cell and gene therapies, mRNA, and oligonucleotides.
2. Advanced Therapies
- Description: Solutions for mRNA-LNP production, cell therapy production, gene therapy production, LNP therapeutics, therapeutic oligos.
- Key Features:
- Comprehensive support from research to manufacturing.
- Tools to accelerate the production and commercialization process.
3. Diagnostics
- Description: Tools to accelerate the development and commercialization of diagnostic assays and kits.
- Key Features:
- Support for lab-based molecular and immuno diagnostics, and point-of-care (POC) diagnostics.
- Customized services for reagent characterization, assay development, and lyophilization.
4. Genomics
- Description: Solutions for disease identification and the development of targeted therapies.
- Key Features:
- Optimization of DNA and RNA extraction.
- Technologies for amplification, enrichment, sequencing, and single-cell sequencing.
5. Laboratory Filtration
- Description: Filtration solutions for research labs, QC, and field applications.
- Key Features:
- Devices for analytical testing, cannabis sample prep, environmental monitoring, industrial applications, microbiology, and food and beverage testing.
6. Medical Filtration
- Description: Filtration and membrane solutions for healthcare professionals, medical device manufacturers, and patients.
- Key Features:
- Anesthesia, intensive care ventilation, and surgical gas handling filtration.
- IV filtration, OEM membrane filtration, and water filtration solutions.
7. Protein Research
- Description: Workflow solutions from isolation and sequencing to sample preparation.
- Key Features:
- Protein purification systems and accessories.
- Support for chromatography and biacore analysis.
Recent Developments
1. New Leadership:
- Pierre-Alain Ruffieux joined as Chief Operating Officer.
2. Innovations and Releases:
- Cytiva’s latest FlexFactory platform for oligonucleotides introduced at Ribobay Pharma.
- Supor Prime sterilizing grade filters launched for improved filtration of high concentration biologics.
3. Support and Partnerships:
- Collaboration with AGC Biologics to provide FlexFactory platforms for a new biomanufacturing facility in Japan.
- Continued support for n-Lorem Foundation.
4. Sustainability Efforts:
- Published the Global Biopharma Sustainability Review examining biopharma sustainability efforts.
- Committed to Net Zero GHG emission reduction targets.
5. Product Developments:
- New cell lines to meet the demands of viral vector manufacturing.
- Innovative tools for next generation cell therapy manufacturing.
6. Customer Support:
- Remote troubleshooting tools like OptiRun™ View aiding in customer support.
Summary
Cytiva is a global life sciences leader with a mission to transform human health through therapeutic advancements. They support biopharma across various stages of therapeutic development with innovative products, detailed process support, and a strong emphasis on sustainability. Recently, they have enhanced their filament technology, entered into strategic partnerships, and launched new products to sustain their market position in the rapidly evolving biopharma industry.